In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Track this case

Case Number:

2:17-md-02785

Court:

Kansas

Nature of Suit:

Personal Inj. Prod. Liability

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Daniel D. Crabtree

Firms

Companies

Sectors & Industries:

February 04, 2021
No Thanks, EpiPen Buyers Tell Judge After Trial Delay Invite

EpiPen buyers accusing Pfizer and Mylan of inflating prices of the drug said they don't want to move an upcoming antitrust multidistrict trial date in the case, noting that their head trial attorney is ready to move ahead with a September date.
January 25, 2021
EpiPen Buyers Want Remote Testimony In Pricing MDL

EpiPen buyers have urged a Kansas federal court to grant their request for livestreamed testimony during an upcoming antitrust multidistrict trial accusing Pfizer and Mylan of inflating prices of the drug, saying it is the only way the jury can hear live testimony from critical witnesses.
January 11, 2021
Mylan, Pfizer Fight Remote Testimony In EpiPen Trial

Drugmakers Pfizer and Mylan told a federal judge it wouldn't be right to give blanket permission for livestreamed testimony in an upcoming trial in the EpiPen antitrust multidistrict litigation.
December 17, 2020
EpiPen Trial Not Feasible Nor Prudent Amid Virus, Judge Says

A Kansas federal judge has postponed an April trial date for Pfizer and Mylan to face consumer class claims in multidistrict litigation alleging they illegally inflated EpiPen prices, finding it would be "not feasible" or prudent to hold a trial while the COVID-19 pandemic is raging.
December 15, 2020
Mylan Tries To Escape Pharmacy's EpiPen Antitrust Suit

Mylan Pharmaceuticals has urged a Kansas federal judge to drop it from a suit alleging it inflated the price for the emergency allergy medication EpiPen, arguing the retail and online pharmacy operator behind the suit not only failed to show it is a direct purchaser but also failed to state an antitrust claim at all.
October 06, 2020
Mylan Says 3rd Circ. Ruling Can't Boost EpiPen Antitrust Suit

Mylan told a Kansas federal judge on Monday that Sanofi is wrong to argue that a recent Third Circuit order, which also wiped out a $448 million AbbVie penalty over pay-for-delay claims, supports the French drugmaker's allegations that Mylan violated antitrust law to maintain EpiPen's dominance.
July 16, 2020
Pfizer, Mylan Push To Pare Down EpiPen Class Action

EpiPen manufacturer Pfizer and distributor Mylan asked a Kansas federal judge to pare down remaining claims in multidistrict litigation over the price of the emergency allergy treatment, saying EpiPen buyers failed to show how the companies conspired to delay the entry of generic competitors.
May 26, 2020
Pfizer, Mylan Can't Quickly Appeal EpiPen RICO Class Cert.

EpiPen manufacturer Pfizer and distributor Mylan cannot immediately appeal a Kansas federal judge's certification of a nationwide class under the Racketeer Influenced and Corrupt Organizations Act in multidistrict litigation over the price of the emergency allergy treatment, the Tenth Circuit ruled Tuesday, finding the district court's conclusions "well-supported."
May 18, 2020
Mylan Pushes For Mediation In EpiPen Antitrust Suit

Mylan has urged a Kansas federal judge to compel a pharmacy operator to mediate its proposed class action over the price of emergency allergy medication EpiPen, saying the company is bound by a contract that requires it to enter mediation before filing a suit.
May 02, 2020
EpiPen Buyers Lost Bid To Depose Ex-Teva CEO In MDL

A Kansas federal judge has rejected EpiPen buyers' request for an order requiring testimony from a former CEO and a current employee of Teva Pharmaceuticals over price-fixing claims in multidistrict litigation over an alleged scheme to inflate prices for the emergency allergy medication.